Publications

Diabetes and infectious disease mortality in Mexico City.

Bragg F. et al, (2023), BMJ open diabetes research & care, 11

Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.

Chapman D. et al, (2023), Kidney Int

Body Composition and Risk of Vascular-Metabolic Mortality Risk in 113 000 Mexican Men and Women Without Prior Chronic Disease.

Gnatiuc Friedrichs L. et al, (2023), J Am Heart Assoc

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study.

Donovan K. et al, (2023), Clin J Am Soc Nephrol, 18, 17 - 27

Sex and Gender in Randomized Controlled Trials of Adults Receiving Maintenance Dialysis: A Meta-epidemiologic Study.

Collister D. et al, (2022), Am J Kidney Dis

Range and Consistency of Cardiovascular Outcomes Reported by Clinical Trials in Kidney Transplant Recipients: A Systematic Review

Wilson GJ. et al, (2022), Transplantation Direct, 9

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.

Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801

Adiposity and NMR-measured lipid and metabolic biomarkers among 30,000 Mexican adults.

Aguilar-Ramirez D. et al, (2022), Commun Med (Lond), 2

Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med

Estimating individual lifetime risk of incident cardiovascular events in adults with type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2)

Bleken Østergaard H. et al, (2022), European Journal of Preventive Cardiology

Bioimpedance in CKD: an Untapped Resource?

HERRINGTON W. and Mayne K., (2022), Nephrology Dialysis Transplantation

Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.

Staplin N. et al, (2022), Hypertension

Bioimpedance indices of fluid overload and cardiorenal outcomes in heart failure and chronic kidney disease: a systematic review

Mayne K. et al, (2022), Journal of Cardiac Failure

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group None., (2022), Nephrol Dial Transplant, 37, 1317 - 1329

Body mass index and COVID-19 mortality: prospective study of 120 000 Mexican adults.

Alegre-Díaz J. et al, (2022), Int J Epidemiol

In CKD, the Kidney Failure Risk Equation predicted 2-y risk for ESKD better than eGFR alone.

Aguilar-Ramirez D. and Herrington WG., (2022), Ann Intern Med

In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes.

Mayne KJ. and Herrington WG., (2022), Annals of internal medicine, 175

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

HPS3/TIMI55-REVEAL Collaborative Group None. et al, (2022), Eur Heart J, 43, 1416 - 1424

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676

Cookies on this website

Publications